Production (Stage)
Avidity Biosciences, Inc.
RNA
$30.54
-$0.045-0.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -55.60% | 35.57% | -17.10% | -11.70% | 58.67% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -55.60% | 35.57% | -17.10% | -11.70% | 58.67% |
| Cost of Revenue | 48.87% | 81.05% | 61.79% | 49.84% | 39.92% |
| Gross Profit | -54.71% | -83.02% | -66.74% | -53.37% | -39.00% |
| SG&A Expenses | 141.76% | 75.80% | 69.52% | 68.85% | 15.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 64.86% | 79.82% | 63.52% | 54.09% | 34.93% |
| Operating Income | -70.39% | -81.28% | -67.39% | -56.98% | -34.01% |
| Income Before Tax | -68.14% | -69.18% | -53.55% | -50.54% | -31.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -68.14% | -69.18% | -53.55% | -50.54% | -31.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -68.14% | -69.18% | -53.55% | -50.54% | -31.42% |
| EBIT | -70.39% | -81.28% | -67.39% | -56.98% | -34.01% |
| EBITDA | -70.79% | -81.85% | -67.80% | -57.26% | -33.81% |
| EPS Basic | -13.48% | -0.13% | 7.77% | -0.52% | -6.13% |
| Normalized Basic EPS | -13.48% | -0.14% | 7.77% | -0.51% | -6.13% |
| EPS Diluted | -13.92% | -0.13% | 7.77% | -0.52% | -6.20% |
| Normalized Diluted EPS | -13.48% | -0.14% | 7.77% | -0.51% | -6.13% |
| Average Basic Shares Outstanding | 48.18% | 68.96% | 66.50% | 49.78% | 23.82% |
| Average Diluted Shares Outstanding | 48.18% | 68.96% | 66.50% | 49.78% | 23.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |